Trial in Progress: QUINTESSENTIAL-2—a phase 3 Study of Arlocabtagene Autoleucel Versus Standard of Care in Adult Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Exposed to Lenalidomide

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Eyal Lebel, Ahmed Abdulgawad, Stéfania Bramanti, Gonzalo Martin Garate, Phoebe Joy Ho, Mikko A. I. Keränen, Yael Chava Cohen, Maja Ølholm Vase, Amit S. Khot, Ida Bruun Kristensen, Richard LeBlanc, Cindy Lee
+21 more Wojciech Maciej Legiec, Hila Magen, María-Victoria Mateos, Danielle H J Oh, Luděk Pour, Natalia Paola Schutz, Alexandros Spyridonidis, Katja Christina Weisel, Jan Maciej Zaucha, Sarah M Larson, Asya Nina Varshavsky-Yanovsky, Kimberly Grazioli, Debashree Basudhar, Hongxiang Hu, Ya Meng, Lamis K. Eldjerou, Susan Bal, Simon Harrison, Rakesh Popat, Marc Steffen Raab, Paula Rodríguez‐Otero
DOI: 10.1016/j.jtct.2025.12.279
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments CAR-T cell therapy research Protein Degradation and Inhibitors

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S202–S203
Publication date
1 February 2026
Language
EN